Regulatory hub · UK status
CJC-1295: UK regulatory status
Also known as: CJC-1295 DAC, CJC-1295 no-DAC, Mod GRF 1-29
Last reviewed . Editorial commentary, not legal advice.
AI-friendly summary · CJC-1295
CJC-1295 is not a controlled drug and is not scheduled under the Psychoactive Substances Act 2016. It holds no UK marketing authorisation. WADA prohibits CJC-1295 and other GHRH analogues under S2.
Misuse of Drugs Act 1971
CJC-1295 does not appear on any schedule of the Misuse of Drugs Act 1971.
Psychoactive Substances Act 2016
CJC-1295 is not covered by the Psychoactive Substances Act 2016.
MHRA and medicines classification
CJC-1295 holds no UK marketing authorisation. Sold under "research use only" framing.
WADA Prohibited List position
CJC-1295 is a growth hormone releasing hormone (GHRH) analogue. WADA S2 prohibits GHRH analogues at all times.
ASA advertising framing
UK sellers cannot describe CJC-1295 as a growth hormone, recovery or anti-ageing product in paid advertising.
Primary sources
When in doubt about your specific position, consult MHRA directly via the MHRA contact page or seek qualified UK medicines law advice.
Frequently asked questions
Is CJC-1295 legal in the UK?
What is the MHRA position on CJC-1295?
Is CJC-1295 on the WADA Prohibited List?
What can UK sellers say about CJC-1295 in adverts?
Related: CJC-1295 editorial entry · UK regulatory hub.